Zhejiang Orient Gene Biotech Co Ltd Market Cap ($524.81 Million)
Market Cap & Net Worth: Zhejiang Orient Gene Biotech Co Ltd (688298)
Zhejiang Orient Gene Biotech Co Ltd market cap. Zhejiang Orient Gene Biotech Co Ltd (SHG:688298) has a market capitalization of $524.81 Million (CN¥3.59 Billion) as of November 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #11686 globally and #3344 in its home market, demonstrating a -3.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Orient Gene Biotech Co Ltd's stock price CN¥17.79 by its total outstanding shares 201600000 (201.60 Million). Also see how efficiently does Zhejiang Orient Gene Biotech Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Zhejiang Orient Gene Biotech Co Ltd Market Cap History (2020–2026)
Zhejiang Orient Gene Biotech Co Ltd market cap history from 2020 to 2026. Data shows change from $3.16 Billion to $524.81 Million (-19.47% CAGR). Check Zhejiang Orient Gene Biotech Co Ltd stock price for real-time trading data and today's change.
Zhejiang Orient Gene Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Orient Gene Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Zhejiang Orient Gene Biotech Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.05x
Zhejiang Orient Gene Biotech Co Ltd's market cap is 1.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.16 Billion | $3.27 Billion | $1.68 Billion | 0.97x | 1.88x |
| 2021 | $3.66 Billion | $10.17 Billion | $4.92 Billion | 0.36x | 0.74x |
| 2022 | $1.80 Billion | $8.77 Billion | $2.07 Billion | 0.20x | 0.87x |
| 2023 | $1.05 Billion | $820.16 Million | -$397.58 Million | 1.29x | N/A |
| 2024 | $865.25 Million | $827.92 Million | -$529.02 Million | 1.05x | N/A |
Competitor Companies of 688298 by Market Capitalization
Companies near Zhejiang Orient Gene Biotech Co Ltd in the global market cap rankings as of November 7, 2026. Also see 688298 total asset value for a full breakdown of the balance sheet.
Key companies related to Zhejiang Orient Gene Biotech Co Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #106 globally with a market cap of $196.11 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #181 globally with a market cap of $128.53 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #234 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #106 | Abbott Laboratories | NYSE:ABT | $196.11 Billion | $113.60 |
| #181 | Stryker Corporation | NYSE:SYK | $128.53 Billion | $335.08 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $104.84 |
| #234 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Zhejiang Orient Gene Biotech Co Ltd (2020–2026)
Market capitalization of Zhejiang Orient Gene Biotech Co Ltd from 2020 to today. Between 2020 and today, Zhejiang Orient Gene Biotech Co Ltd's market cap moved from $3.16 Billion to $ 524.81 Million, with a yearly change of -19.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥524.81 Million | -24.07% |
| 2025 | CN¥691.19 Million | -20.12% |
| 2024 | CN¥865.25 Million | -17.98% |
| 2023 | CN¥1.05 Billion | -41.26% |
| 2022 | CN¥1.80 Billion | -50.91% |
| 2021 | CN¥3.66 Billion | +15.94% |
| 2020 | CN¥3.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Zhejiang Orient Gene Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $524.81 Million USD |
| MoneyControl | $524.81 Million USD |
| MarketWatch | $524.81 Million USD |
| marketcap.company | $524.81 Million USD |
| Reuters | $524.81 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more